Mayo Clinic does not endorse the alternative party products and services advertised. Do not take other medicines unless they have been discussed with your physician. This includes prescription or nonprescription (over-the-counter ) medicines and herbal or nutritional vitamin supplements. While you are being treated with chloroquine, do not have any immunizations without your doctor’s approval. Using this medicine for years may cause muscle weakness. Check with your doctor straight away if you have muscle weakness while using this medicine.
Check with your doctor immediately if blurred vision, difficulty with reading, or any other change in vision occurs during or after treatment. Your physician might want your eyes be checked by an ophthalmologist . Do not drive or do other things that might be dangerous until you know how this medicine influences you. If these reactions are especially bothersome, check with your doctor. Ask your doctor the way you should dispose of any medicine you do not use. The consequences may be increased due to slower removal of chloroquine from the body.
I trust the thoughts and opinions of Harvey Risch a lot more than the in the offing guy. Strange, for six+ months now people have been raving about HCQ. You’ve had half a year to run a proper clinical trial and yet you won’t. Those will be the doses that gave blood levels on par with what was felt to be needed to kill the virus.
If you ask me, if drug A works just a little, and drug B works a lttle bit, then combining the two gives you a better result than utilizing a or B alone. In contrary, if drug A does nothing for the individual, and drug B does something good, then any benefits to the patient are purely drug B and drug A is just an expensive placebo at best. Agreed , but my point was just to illustrate the double standard at play here. The remdesivir trial was also under-powered to demonstrate a mortality benefit in the pre-specified statistical analysis. The mortality benefit claims here are based on post-hoc analysis , and mainly focused on an individual subgroup , both practices which are normally disparaged on this website – properly – to be bad science. Not only that , the top confidence intervals in a number of of the subgroups run to relative risk ratios of just one 1.9 – 4 , suggesting that in a fresh trial , you may even demonstrate a mortality upsurge in those subgroups.
The presymptomatic phase lasts about 5 days per Marik. The initial immune response phase lasts another 8 days per Marik. From then on possibly comes the immune hyper-response phase. Even when we get high quality trials that show that mono clonal antibodies and remdesivir work fantastically, we still have problems. How do we get enough Rapid Antigen Tests or Home Everyday Antigen Rapid Tests to the right people so that we could start treatment early enough to be of great benefit? Although we get the tests, we still are having issues on knowing who to treat and having enough of the treatments on hand.
Saint Joseph’s College is the city that grows community, preparing whole visitors to contribute to a complete world. We’ve made the price of school transparent, clear, and designed around you. Please see drug monograph at and/or contact company for full drug labeling. If I have been a virologist or an immunologist or an infectious disease expert or an MD, I will be expected to learn better.
There’s also the Big Money known reasons for Big Pharma to actively subvert acceptance of Avifavir by FDA. I’m wondering if this would be worth starting a discussion from your end about how exactly those exogenous factors that may impact access to clinically and affordable treatments in the U.S. Favipiravir is likely to be teratogenic, as much as i know. Favipiravir might be teratogenic, according to Wikipedia. I don’t know whether that counts a lot of r a drug like this? Especially as the chance groups aren’t likely to be pregnant.
Is it ethical to even consider testing a drug that’s not intended for nor is likely to benefit patients with 25% death risk? IMHO in such situations you need to only consider drugs that have a reasons to work better than the typical treatment, a strategy much like rules for clinical research in emergency rooms. The info from the HCQ outpatient randomized clinical trials show that the HCQ groups constantly did clinically better than the control groups. “Outpatient” means early treatment or prophylaxis before admission to hospital, as is practiced by Raoult’s IHU hospital in France, by Zelenko in NY, by India, by Senegal and far of Africa and so on .